OPM sensors for Aura

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Aura+1 More
OPM sensors - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help researchers learn if an atomic magnetometer can be used for brain imaging, and if it is as effective as the current method which uses a SQUID-based cryogenic sensor.

Eligible Conditions
  • Aura

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 1 day (during the brain scan)

Day 1
Evoked and Induced MEG with OPM and SQUID sensors in healthy controls
Spontaneous MEG with OPM and SQUID sensors in patients with epilepsy

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

healthy adults
1 of 2
Patients with intractable epilepsy
1 of 2
Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: OPM sensors · No Placebo Group · N/A

healthy adultsExperimental Group · 2 Interventions: SQUID sensors, OPM sensors · Intervention Types: Device, Device
Patients with intractable epilepsyExperimental Group · 2 Interventions: SQUID sensors, OPM sensors · Intervention Types: Device, Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 day (during the brain scan)

Who is running the clinical trial?

University of Colorado, BoulderOTHER
108 Previous Clinical Trials
27,615 Total Patients Enrolled
University of Colorado, DenverLead Sponsor
1,568 Previous Clinical Trials
1,923,369 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 10th, 2021

Last Reviewed: October 21st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.